# Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)

> **NCT04772534** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 314 (actual)

## Conditions studied

- Papillomavirus Infections

## Interventions

- **BIOLOGICAL:** 9vHPV vaccine

## Key facts

- **NCT ID:** NCT04772534
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-17
- **Primary completion:** 2024-04-06
- **Final completion:** 2024-04-06
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04772534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04772534, "Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT04772534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*